FY2026 medical budget lines and team-level resource capacity. All figures USD; FY2026 exchange-rate snapshot of 2 Jan 2026.
Planned
Committed
Actual
Forecast at year end
Overrun-risk rule (MET-071): committed > planned, or actual ÷ planned > 0.75 × 1.05 = 78.75% with 71% of the fiscal year elapsed. Forecast is a straight-line assumption: actual ÷ 0.71. It ignores seasonality and known one-off commitments.
USD millions
| Product | Planned | Committed | Actual |
|---|---|---|---|
| Aurelin | $1.08M | $0.75M | $0.52M |
USD millions, sorted by planned
Largest category: Personnel ($0.62M planned). 5 categories in the current filter.
MET-070 monthly history (Global, % of planned) against an even 1/12-per-month plan line. Filters do not apply to this series.
Latest: 71% consumed by Sep versus 75% on the straight line. Consumption above the line means spend is running ahead of an even phasing.
| Line | Product | Region | Function | Category | Initiative | Vendor | Planned | Committed | Actual | Variance | Consumed | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BL-026 | Aurelin | Global | Leadership | Personnel | — | — | $620k | $620k | $470k | $150k | 76% | On plan |
| BL-027 | Aurelin | Global | Medical Communications | Publication | — | — | $110k | $90k | $42k | $68k | 38% | On plan |
| BL-028 | Aurelin | Global | Leadership | Consultancy | INI-0401 | — | $120k | $0 | $0 | $120k | 0% | On plan |
| BL-029 | Aurelin | Global | Medical Communications | Congress | — | — | $45k | $40k | $12k | $33k | 27% | On plan |
| BL-030 | Aurelin | Global | Evidence Generation | Research | — | — | $180k | $0 | $0 | $180k | 0% | On plan |
Team-level analytics only
8 of 10 teams have demand above capacity.
| Team | Region | Function | Capacity FTE | Demand FTE | Utilisation | Contractor FTE | Critical roles | Allocations by initiative |
|---|---|---|---|---|---|---|---|---|
| Field Medical — US Oncology | North America | Field Medical | 8 | 8.6 | 108% | 0 |
| |
| Field Medical — EU Oncology | Europe | Field Medical | 10 | 10.2 | 102% | 1 | — | |
| Field Medical — Japan | Asia-Pacific | Field Medical | 1 | 2 | 200% | 0 |
|
|
| Field Medical — Nephrology | Europe | Field Medical | 3 | 3.4 | 113% | 0 |
| |
| Field Medical — Neurology | Global | Field Medical | 6 | 5.1 | 85% | 0 | — | |
| Medical Communications | Global | Medical Communications | 5 | 6.1 | 122% | 2 |
| |
| Medical Information | Global | Medical Information | 9 | 9.8 | 109% | 1 | — | |
| Evidence Generation & HEOR | Global | Evidence Generation | 4 | 4.9 | 123% | 1 |
| |
| Medical Operations | Global | Medical Operations | 3 | 2.8 | 93% | 0 | — | Not allocated to initiatives |
| Compliance & Quality (MA-aligned) | Global | Compliance | 1 | 1.7 | 170% | 0 |
| Not allocated to initiatives |